Baseline resistance mutations and virological response to dolutegravir in treatment-naïve patients: a multicentre NGS study
Por:
Inciarte, A, Berrocal, L, Santos, JR, Aleman, MR, Curran, A, Gonzalez, RM, Bernal, S, De Lazzari, E, del Toro, MG, Raventós, B, Lirola, AML, Martínez, E, Paredes, R and Blanco, JL
Publicada:
1 abr 2026
Resumen:
Objectives To assess the prevalence of transmitted drug resistance mutations (TDRMs) and the impact of pre-existing resistance mutations, including minority variants, on virological response in ART-na & iuml;ve individuals initiating dolutegravir-based triple therapy using next-generation sequencing (GRT-NGS). Methods A multicentre, retrospective cohort study was conducted including ART-na & iuml;ve individuals who started a dolutegravir-3DR between 2015 and 2019. Baseline GRT-NGS Illumina (R), covering RT, PR and IN genes identified primary (P-DRM) and secondary/polymorphic (S/p-DRM) mutations in high-abundance drug resistance variants (HA-DRVs; >= 20%) and low-abundance drug resistance variants (LA-DRVs; 1%-19%). Virological failure (VF) was defined as two consecutive HIV-1 RNA >= 50 copies/mL. Virological response was assessed at Weeks 48 and 96. Results Of 326 participants, 86% were male and 72% were MSM; 78% received DTG/ABC/3TC and 22% TDF/FTC + DTG. At least one TDRM was detected in 24% and any DRM in 48% of subjects. Virological suppression was achieved in 76% by intention-to-treat (ITT), 97% on-treatment (OT) and 56% (ITT), 94% (ITT) at Weeks 48 and 96, respectively. VF occurred in 11 subjects (3.4%), mostly within 48 weeks, all with low-level viraemia (<1000 copies/mL; 8 < 200 copies/mL) and no emergent of new DRM in HA-DRVs with phenotypic impact. Among those with pre-existing DRM, including 36 P-HA-DRVs, 79 S/p-HA-DRVs, 57 P-LA-DRVs and 45 S/P-LA-DRVs, no significant association with VF was observed. Conclusions Our findings indicate that pre-existing IN and RT DRM, including low-abundance and secondary/polymorphic variants, did not compromise the virological efficacy of dolutegravir-based triple therapy in ART-na & iuml;ve individuals, supporting the high resistance barrier of dolutegravir and the lack of need for baseline resistance testing.
Filiaciones:
Inciarte, A:
Hosp Clin Barcelona, Barcelona, Spain
Inst Invest Med August Pi i Sunyer IDIBAPS, Barcelona, Spain
Berrocal, L:
Hosp Clin Barcelona, Barcelona, Spain
Inst Invest Med August Pi i Sunyer IDIBAPS, Barcelona, Spain
:
Hosp Univ Germans Trias i Pujol, Badalona, Spain
Aleman, MR:
Hosp Univ Canarias, San Cristobal la Laguna, Spain
Curran, A:
Hosp Univ Vall dHebron, Vall dHebron Res Inst VHIR, Barcelona, Spain
Gonzalez, RM:
Consorcio Hosp Gen Univ, Valencia, Spain
Bernal, S:
Hosp Univ Virgen de Valme, Seville, Spain
De Lazzari, E:
Hosp Clin Barcelona, Barcelona, Spain
Inst Invest Med August Pi i Sunyer IDIBAPS, Barcelona, Spain
Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERInfec, Madrid, Spain
del Toro, MG:
Consorcio Hosp Gen Univ, Valencia, Spain
Raventós, B:
Hosp Univ Vall dHebron, Vall dHebron Res Inst VHIR, Barcelona, Spain
Lirola, AML:
Hosp Univ Canarias, San Cristobal la Laguna, Spain
Martínez, E:
Hosp Clin Barcelona, Barcelona, Spain
Inst Invest Med August Pi i Sunyer IDIBAPS, Barcelona, Spain
Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERInfec, Madrid, Spain
:
Hosp Univ Germans Trias i Pujol, Badalona, Spain
Blanco, JL:
Hosp Clin Barcelona, Barcelona, Spain
Inst Invest Med August Pi i Sunyer IDIBAPS, Barcelona, Spain
Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERInfec, Madrid, Spain
|